Speculation over a return for Vioxx

The FDA's decision to allow Pfizer's Celebrex to remain on the market yesterday has led to speculation by some that Merck's Vioxx could also return, should the company seek its re-introduction.
A report published today on the business Web site Marketwatch.com said some investors are hoping Vioxx may make a comeback. In the report, Merck said it looked forward to discussions with the FDA over Vioxx but would not confirm whether negotiations with the agency had already begun.
During yesterday's briefing on marketing changes for non-steroidal anti-inflammatory drugs (NSAIDs), the FDA said it would "carefully review any proposal from Merck" for resuming the marketing of Vioxx and would likely discuss the review with the new FDA Drug Safety Oversight Board and an Advisory Committee before making a final decision.
In a statement yesterday, Merck added that while it respects the FDA's position on use of NSAIDs and cardiac trouble in some patients, it also believes there is still a patient need for the drugs.
You must be a registered member of MMM to post a comment.
 

Did you miss January's Top 40 Healthcare Transformers issue? Read how these inventors, strategists, entrepreneurs and wonks are challenging, disrupting and otherwise transforming the healthcare business. And join us April 30 to honor them at the Transforming Healthcare Dinner. Click here.